Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolebrutinib in Nonrelapsing Secondary Progressive MS
NCT04411641Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of tolebrutinib in secondary-progressive multiple sclerosis (SPMS), sponsored by Sanofi. Started Sep 2020; status: completed.
02
Drugs
tolebrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT04411641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411641.